Document:EU CHMP Guidelines -: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
Migrate to Template:DocumentData for PageForms (GxPlexBot) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{DocumentData | |||
|reference=EU CHMP Guidelines - | |reference=EU CHMP Guidelines - | ||
|validity_area=EU | |validity_area=EU | ||
Latest revision as of 12:54, 16 July 2026
| Document information | |
|---|---|
| Reference | EU CHMP Guidelines - |
| Validity area | EU |
| Scope(s) | HM |
| Document name | CHMP Guidelines |
| Version / Revision | - |
| Status | N.A. |
| Document type | Corpus of texts |
| Language(s) | EN |
| Description | The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for human medicines.
Clinical efficacy and safety guideline categories : - Alimentary tract and metabolism - Blood and blood forming organs - Blood products (including biotechnological alternatives) - Cardiovascular system - Dermatologicals - Genito-urinary system and sex hormones - Anti-infectives for systemic use - Antineoplastic and immunomodulating agents - Rheumatology/musculoskeletal system - Nervous system - Respiratory system - Orally inhaled products - Radiopharmaceuticals and diagnostic agents - Allergy/Immunology - Biostatistics - General (Including ICH guidelines E1 To be noted: - INS/GCP/46309/2012 – Classification and analysis of the GCP inspection findings of GCP inspections conducted at the request of the CHMP |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
No references yet.
